Discover our latest clinical research

Featured Publication

Our rigorous clinical research shows the Mirvie RNA platform can predict preeclampsia and preterm birth months in advance.1,2,3

Nature Magazine Logo

Study published in Nature shows Mirvie can predict pregnancy complications months before they happen using new, proprietary RNA platform

South San Francisco, CA - January 5, 2022

Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the publication of a study in Nature proving the proprietary Mirvie RNA platform is first to predict unexpected complications by revealing the underlying biology of each pregnancy. The research analyzed the largest and most diverse dataset of maternal transcriptomes to date. The platform opens a new window into pregnancy health for women to act and their doctors to intervene before unexpected complications become a crisis.

Read More
Nature Magazine Logo

Mirvie is redefining pregnancy health by developing the first early detection RNA test to address pregnancy complications which impact 45 million women globally

South San Francisco, CA - April 27, 2021

Pregnancy complications affect 45 million women globally each year, five times the rate of cancer incidence. Today there is no reliable way to identify those pregnancies at-risk. The goal of Mirvie’s simple blood test is the early detection of complications such as preterm birth, preeclampsia and gestational diabetes, which has the potential to reduce pregnancy healthcare costs by up to 65%.

Read More